Key facts
- Deep Track Capital, LP filed SCHEDULE 13G/A for Viridian Therapeutics, Inc. Common Stock, $0.01 par value per share (VRDN).
- Disclosed ownership: 2.6%.
- Date of event: 31 Dec 2025.
Deep Track Capital, LP - 31 Dec 2025 SCHEDULE 13G/A Report for Viridian Therapeutics, Inc. Common Stock, $0.01 par value per share (VRDN)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- VRDN
- Shares outstanding
- 95,276,717 shares
- Disclosed Ownership
- 2,524,833 shares
- Ownership
- 2.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 08:53:06 UTC
- Date of event
- 31 Dec 2025
- Next filing
- 08 May 2026
- SEC
- View on sec.gov
Key filing fact
Deep Track Capital, LP disclosed 2.6% ownership in Viridian Therapeutics, Inc. Common Stock, $0.01 par value per share (VRDN) on 31 Dec 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2026, 08:53.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 2.6% | 2,524,833 | 0 | 2,524,833 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 2.6% | 2,524,833 | 0 | 2,524,833 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 2.6% | 2,524,833 | 0 | 2,524,833 | /s/ David Kroin | David Kroin |
CIK / CUSIP context first